The synthesis, hypoglycemic activity and acute toxicity of new imidazole-thiazolidines hybrid structures


  • V. O. Chornous Bukovinian State Medical University, Ukraine
  • O. Ya. Melnyk SHHE «Ivano-Frankivsk National Medical University», Ukraine
  • O. M. Hliebov SHHE «Ivano-Frankivsk National Medical University», Ukraine
  • M. V. Tykhonenko SHHE «Ivano-Frankivsk National Medical University», Ukraine
  • L. M. Sheremeta SHHE «Ivano-Frankivsk National Medical University», Ukraine
  • O. K. Yarosh Institute of Pharmacology and Toxicology of the AMS of Ukraine, Ukraine
  • O. M. Denysenko Institute of Organic Chemistry of the NAS of Ukraine, Ukraine
  • R. V. Rodik Institute of Organic Chemistry of the NAS of Ukraine, Ukraine
  • M. V. Vovk Institute of Organic Chemistry of the NAS of Ukraine, Ukraine



4-chloro-5-formylimidazoles, 1, 3-thiazolidine-4-one, imidazole-thiazolidine structure, synthesis, hypo- glycemic activity, acute toxicity


The article presents a brief description of diabetes type 2 as a disease related with carbohydrate metabolism disorder mainly caused by insulin resistance and relative insulin defi ciency. It has been noted that pathologies may appear under the action of drugs of the glitazone group; it is a major cause for systematic search for new bioactive and safe compounds with the hypoglycemic action. Considering the wide range of the biological activity of imidazole derivatives and 1,3-thiazolidine the synthesis of new hybrid structures – 5-[(1-aryl-4-chloro-1H-imidazole-5-yl)methylene]-1,3-thiazolidine-2,4-diones and their exohydrated analogues – 5-[(1-aryl-4-chloro-1H-imidazole-5-yl)methyl]-1,3-thiazolidine-2,4-diones has been carried out. A preparative suitable scheme for their obtaining has been proposed, it is based on condensation of available 1-aryl-4-chloro-5-formylimidazoles with1,3-thiazolidine-4-one and further hydrogenation of the exocyclic ylidene bond formed. The results of biomedical studies of the compounds obtained in the doses of 100, 10 and 1 mg/kg have shown that they have a strong hypoglycemic activity, which exceeds the effect of test drug pioglitazone by 55%. The acute toxicity (LD50) of 5-{[1-(4-tolyl)-4chloro-1H-imidazole-5-yl]methylene}-1,3-thiazolidine-2,4-dione is 1292.92 mg/k when injected intraperitoneally.


Download data is not yet available.


  1. Suntsov Yu. I. Sakharnyi diabet, 2012, No.1, pp.6-11.
  2. Сleary P., Orhard T., Zimman B. Coronary calci™ication in the diabetes control and complication trial (DCCT/EDIC) cohort for the DCCT/EDIC study group program and abstract of ADA 63-rd Annual Scienti™ic Session. New Orlean, Louisiana, 2003.
  3. Yarosh O. K. Farmakologiya ta likarska toksykologiya, 2011, No.5(24), pp.390-392.
  4. Turner R. The Lancet, 1998, Vol. 352, pp.837-852.
  5. Kahn S. E., Zimman B., Lachin J. M. Diabetes Care, 2008,Vol. 31, pp.845-851.
  6. Patel A., MacMahon S., Chalmers J. New England Journal of Medicine, 2008, Vol. 358, pp.2560-2572.
  7. Wilcox R., Kupfer S., Erdman E. American Heart Journal, 2008, Vol. 155, pp.712-717.
  8. Halmann R. R., Paul S. K., Bethel M. A. New England Journal of Medicine, 2008, Vol. 359, pp.1577-1589.
  9. Gaede P., Valentine W. J., Palmer A. J. Diabetes Care, 2008, Vol. 31. pp.1510-1515.
  10. Arner P. Diabetes Obesity Metabolism, 2001, Vol. 3, pp.11-19.
  11. Kendall D. M., Sobel B. E., Coulston A. M., Peters H. A. L., McLean B. K., Peragallo-Dottko V., Buse J. B., Fonseca V. A., Hill J. O., Nesto R. W., Sunyer F. X. Coronary Artery Disease, 2003, Vol. 14, pp.335-348.
  12. Ikeda Н. 36-th Annual Meeting of the European Association for the Study of Diabetes. Report, 2000,3.
  13. Aleksandrov A. A., Kukharenko C. C., Yadrikhinskaya M. H., Shatskaya O. A., Drozdova E. N. Lechashchii vrach, 2012, No.11, pp.23-27.
  14. Inzucchi S. E. Journal of American Medicinal Association, 2002, Vol. 287, No.3, pp.360-372.
  15. Mannuci E., Monami M., Lamonna C., Gensini G. F., Marchioni N. Diabets Obes Metabolism, 2008, Vol. 10, No.12, pp.1221-1235.
  16. Middlemis D., Watson. Tetrahedron, 1994, Vol. 50, No.46, pp.13049-1380.
  17. Narasimphan B., Sharma D., Kumar P. Medicinal Chemistry Research, 2011. Vol. 20, No.8, pp.1119-1140.
  18. Mendgen T., Steuer C., Klein C. D. Journal of Medicinal Chemistry, 2012, Vol. 55, No.2. pp.743-753.
  19. Tomašić T., Mašić L. P. Expert Opinion of on Drug Discovery, 2012, Vol. 7, No.7, pp.549-560.
  20. Chornous V. A., Grozav A. N., Rusanov E. B., Nesterenko A. M., Vovk M. V. Zhurnal Organicheskoi Khimii, 2011, Vol. 47, No.5, pp.699-706.
  21. Stefanov O. V. Doklinochni doslidzhennia likars’kykh zasobiv (metodychni rekomendstsii), K.: Vydavnychyi dim “Avitsenna”, 2001, 528 s.
  22. Montsevichute-Eringene E. V. Patologicheskaya phiziologiya, 1964, No.4. pp.71-78.



How to Cite

Chornous, V. O.; Melnyk, O. Y.; Hliebov, O. M.; Tykhonenko, M. V.; Sheremeta, L. M.; Yarosh, O. K.; Denysenko, O. M.; Rodik, R. V.; Vovk, M. V. The Synthesis, Hypoglycemic Activity and Acute Toxicity of New Imidazole-Thiazolidines Hybrid Structures. J. Org. Pharm. Chem. 2016, 14, 46-52.



Original Researches